{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T00:59:35Z","timestamp":1794013175138,"version":"4.8.0"},"reference-count":251,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2008,5,23]],"date-time":"2008-05-23T00:00:00Z","timestamp":1211500800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pain Practice"],"published-print":{"date-parts":[[2008,7]]},"abstract":"<jats:sec>\n                    <jats:title>\u25aa\u2002Abstract<\/jats:title>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary of consensus:<\/jats:title>\n                    <jats:p>\n                      <jats:bold>1.\u2002The use of opioids in cancer pain:\u2002<\/jats:bold>\n                      The criteria for selecting analgesics for pain treatment in the elderly include, but are not limited to, overall efficacy, overall side\u2010effect profile, onset of action, drug interactions, abuse potential, and practical issues, such as cost and availability of the drug, as well as the severity and type of pain (nociceptive, acute\/chronic, etc.). At any given time, the order of choice in the decision\u2010making process can change.\n                    <\/jats:p>\n                    <jats:p>This consensus is based on evidence\u2010based literature (extended data are not included and chronic, extended\u2010release opioids are not covered). There are various driving factors relating to prescribing medication, including availability of the compound and cost, which may, at times, be the main driving factor.<\/jats:p>\n                    <jats:p>The transdermal formulation of buprenorphine is available in most European countries, particularly those with high opioid usage, with the exception of France; however, the availability of the sublingual formulation of buprenorphine in Europe is limited, as it is marketed in only a few countries, including Germany and Belgium. The opioid patch is experimental at present in U.S.A. and the sublingual formulation has dispensing restrictions, therefore, its use is limited.<\/jats:p>\n                    <jats:p>It is evident that the population pyramid is upturned. Globally, there is going to be an older population that needs to be cared for in the future. This older population has expectations in life, in that a retiree is no longer an individual who decreases their lifestyle activities. The \u201cbaby\u2010boomers\u201d in their 60s and 70s are \u201cbaby zoomers\u201d; they want to have a functional active lifestyle. They are willing to make trade\u2010offs regarding treatment choices and understand that they may experience pain, providing that can have increased quality of life and functionality. Therefore, comorbidities\u2014including cancer and noncancer pain, osteoarthritis, rheumatoid arthritis, and postherpetic neuralgia\u2014and patient functional status need to be taken carefully into account when addressing pain in the elderly.<\/jats:p>\n                    <jats:p>World Health Organization step III opioids are the mainstay of pain treatment for cancer patients and morphine has been the most commonly used for decades. In general, high level evidence data (Ib or IIb) exist, although many studies have included only few patients. Based on these studies, all opioids are considered effective in cancer pain management (although parts of cancer pain are not or only partially opioid sensitive), but no well\u2010designed specific studies in the elderly cancer patient are available. Of the 2 opioids that are available in transdermal formulation\u2014fentanyl and buprenorphine\u2014fentanyl is the most investigated, but based on the published data both seem to be effective, with low toxicity and good tolerability profiles, especially at low doses.<\/jats:p>\n                    <jats:p>\n                      <jats:bold>2.\u2002The use of opioids in noncancer\u2010related pain:\u2002<\/jats:bold>\n                      Evidence is growing that opioids are efficacious in noncancer pain (treatment data mostly level Ib or IIb), but need individual dose titration and consideration of the respective tolerability profiles. Again no specific studies in the elderly have been performed, but it can be concluded that opioids have shown efficacy in noncancer pain, which is often due to diseases typical for an elderly population. When it is not clear which drugs and which regimes are superior in terms of maintaining analgesic efficacy, the appropriate drug should be chosen based on safety and tolerability considerations. Evidence\u2010based medicine, which has been incorporated into best clinical practice guidelines, should serve as a foundation for the decision\u2010making processes in patient care; however, in practice, the art of medicine is realized when we individualize care to the patient. This strikes a balance between the evidence\u2010based medicine and anecdotal experience. Factual recommendations and expert opinion both have a value when applying guidelines in clinical practice.\n                    <\/jats:p>\n                    <jats:p>\n                      <jats:bold>3.\u2002The use of opioids in neuropathic pain:\u2002<\/jats:bold>\n                      The role of opioids in neuropathic pain has been under debate in the past but is nowadays more and more accepted; however, higher opioid doses are often needed for neuropathic pain than for nociceptive pain. Most of the treatment data are level II or III, and suggest that incorporation of opioids earlier on might be beneficial. Buprenorphine shows a distinct benefit in improving neuropathic pain symptoms, which is considered a result of its specific pharmacological profile.\n                    <\/jats:p>\n                    <jats:p>\n                      <jats:bold>4.\u2002The use of opioids in elderly patients with impaired hepatic and renal function:\u2002<\/jats:bold>\n                      Functional impairment of excretory organs is common in the elderly, especially with respect to renal function. For all opioids except buprenorphine, half\u2010life of the active drug and metabolites is increased in the elderly and in patients with renal dysfunction. It is, therefore, recommended that\u2014except for buprenorphine\u2014doses be reduced, a longer time interval be used between doses, and creatinine clearance be monitored. Thus, buprenorphine appears to be the top\u2010line choice for opioid treatment in the elderly.\n                    <\/jats:p>\n                    <jats:p>\n                      <jats:bold>5.\u2002Opioids and respiratory depression:\u2002<\/jats:bold>\n                      Respiratory depression is a significant threat for opioid\u2010treated patients with underlying pulmonary condition or receiving concomitant central nervous system (CNS) drugs associated with hypoventilation. Not all opioids show equal effects on respiratory depression: buprenorphine is the only opioid demonstrating a ceiling for respiratory depression when used without other CNS depressants. The different features of opioids regarding respiratory effects should be considered when treating patients at risk for respiratory problems, therefore careful dosing must be maintained.\n                    <\/jats:p>\n                    <jats:p>\n                      <jats:bold>6.\u2002Opioids and immunosuppression:\u2002<\/jats:bold>\n                      Age is related to a gradual decline in the immune system: immunosenescence, which is associated with increased morbidity and mortality from infectious diseases, autoimmune diseases, and cancer, and decreased efficacy of immunotherapy, such as vaccination. The clinical relevance of the immunosuppressant effects of opioids in the elderly is not fully understood, and pain itself may also cause immunosuppression.\n                    <\/jats:p>\n                    <jats:p>Providing adequate analgesia can be achieved without significant adverse events, opioids with minimal immunosuppressive characteristics should be used in the elderly. The immunosuppressive effects of most opioids are poorly described and this is one of the problems in assessing true effect of the opioid spectrum, but there is some indication that higher doses of opioids correlate with increased immunosuppressant effects. Taking into consideration all the very limited available evidence from preclinical and clinical work, buprenorphine can be recommended, while morphine and fentanyl cannot.<\/jats:p>\n                    <jats:p>\n                      <jats:bold>7.\u2002Safety and tolerability profile of opioids:\u2002<\/jats:bold>\n                      The adverse event profile varies greatly between opioids. As the consequences of adverse events in the elderly can be serious, agents should be used that have a good tolerability profile (especially regarding CNS and gastrointestinal effects) and that are as safe as possible in overdose especially regarding effects on respiration. Slow dose titration helps to reduce the incidence of typical initial adverse events such as nausea and vomiting. Sustained release preparations, including transdermal formulations, increase patient compliance.\u2002\u25aa\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/j.1533-2500.2008.00204.x","type":"journal-article","created":{"date-parts":[[2008,5,23]],"date-time":"2008-05-23T06:46:47Z","timestamp":1211525207000},"page":"287-313","source":"Crossref","is-referenced-by-count":687,"title":["Opioids and the Management of Chronic Severe Pain in the Elderly: Consensus Statement of an International Expert Panel with Focus on the Six Clinically Most Often Used World Health Organization step III Opioids (Buprenorphine, Fentanyl, Hydromorphone, Methadone, Morphine, Oxycodone)"],"prefix":"10.1111","volume":"8","author":[{"given":"Joseph","family":"Pergolizzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer H","family":"B\u00f6ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Budd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Dahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serdar","family":"Erdine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Hans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans\u2010Georg","family":"Kress","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Langford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf","family":"Likar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert B.","family":"Raffa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Sacerdote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,7,18]]},"reference":[{"key":"e_1_2_9_2_2","unstructured":"Agency for Health Care Policy and Research.Acute pain management: operative or medical procedures and trauma. No. 1. Rockville MD; 1993. 107."},{"key":"e_1_2_9_3_2","doi-asserted-by":"publisher","DOI":"10.1213\/01.ANE.0000068580.00245.95"},{"key":"e_1_2_9_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(96)00019-4"},{"key":"e_1_2_9_5_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.323.7308.334"},{"key":"e_1_2_9_6_2","volume-title":"Method for Evaluating Research and Guideline Evidence (MERGE)","author":"Liddle J","year":"1996"},{"key":"e_1_2_9_7_2","unstructured":"World Health Organization Regional Office for Europe. Better palliative care for older people. Booklet edited byDaviesE HigginsonIJ2004."},{"key":"e_1_2_9_8_2","volume-title":"Epidemiology of pain","author":"Code B","year":"2001"},{"key":"e_1_2_9_9_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.16.2081-a"},{"key":"e_1_2_9_10_2","unstructured":"National Statistics Online.http:\/\/www.statistics.gov.uk\/."},{"key":"e_1_2_9_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)03057-3"},{"key":"e_1_2_9_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0749-0690(05)70079-3"},{"key":"e_1_2_9_13_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-200522080-00002"},{"key":"e_1_2_9_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002508-200407000-00004"},{"key":"e_1_2_9_15_2","doi-asserted-by":"publisher","DOI":"10.1185\/030079904X2114"},{"key":"e_1_2_9_16_2","volume-title":"Geriatric Pain","author":"Harkins S","year":"1994"},{"key":"e_1_2_9_17_2","doi-asserted-by":"publisher","DOI":"10.1185\/030079902125001272"},{"key":"e_1_2_9_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1980.241"},{"key":"e_1_2_9_19_2","doi-asserted-by":"publisher","DOI":"10.1185\/03007998609110446"},{"key":"e_1_2_9_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/AJP.0b013e3181673b65"},{"key":"e_1_2_9_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cacc.2005.01.007"},{"key":"e_1_2_9_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3959(93)90165-L"},{"key":"e_1_2_9_23_2","first-page":"233","article-title":"Transdermal drug delivery and its application to pain control","volume":"14","author":"Caplan R","year":"1990","journal-title":"Adv Pain Res Ther."},{"key":"e_1_2_9_24_2","first-page":"S11","article-title":"Transdermal buprenorphine in the treatment of neuropathic pain","volume":"11","author":"Rodriguez\u2010Lopez M.","year":"2004","journal-title":"Rev Soc Esp Dolor."},{"key":"e_1_2_9_25_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pa.32.040192.001415"},{"key":"e_1_2_9_26_2","volume-title":"Buprenorphine in Patients with Increased Vulnerability to Potential Opioid Adverse Effects","author":"Kress H.","year":"2005"},{"key":"e_1_2_9_27_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-199101000-00001"},{"key":"e_1_2_9_28_2","doi-asserted-by":"publisher","DOI":"10.1093\/gerona\/54.6.B239"},{"key":"e_1_2_9_29_2","unstructured":"PDR Physicians Desk Reference2004.http:\/\/www.PDR.net"},{"key":"e_1_2_9_30_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.172"},{"issue":"1","key":"e_1_2_9_31_2","doi-asserted-by":"crossref","first-page":"s17","DOI":"10.1191\/0269216306pm1127oa","article-title":"Renal impairment. a challenge for opioid treatment? The role of buprenorphine","volume":"20","author":"Boger RH.","year":"2006","journal-title":"Palliat Med."},{"key":"e_1_2_9_32_2","doi-asserted-by":"crossref","first-page":"s17","DOI":"10.1191\/0269216306pm1127oa","article-title":"Renal impairment. a challenge for opioid treatment? The role of buprenorphine","volume":"20","author":"Boeger RH.","year":"2006","journal-title":"Palliative Med."},{"key":"e_1_2_9_33_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1532-5415.50.6s.1.x"},{"key":"e_1_2_9_34_2","doi-asserted-by":"crossref","first-page":"637","DOI":"10.2147\/CIA.S1939","article-title":"Pharmacological pain management in the elderly patient","volume":"2","author":"McCleane G.","year":"2007","journal-title":"Clin Interv Aging."},{"key":"e_1_2_9_35_2","doi-asserted-by":"publisher","DOI":"10.1097\/SMJ.0b013e3180f626ff"},{"key":"e_1_2_9_36_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4637.2007.00260.x"},{"key":"e_1_2_9_37_2","first-page":"54","article-title":"Opioids and treatment of chronic pain: understanding pain patterns and the role for rapid\u2010onset opioids","volume":"7","author":"Simon S.","year":"2005","journal-title":"Medgenmed."},{"key":"e_1_2_9_38_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1444-0903.2004.t01-9-.x"},{"key":"e_1_2_9_39_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1995.03530230056031"},{"key":"e_1_2_9_40_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.10.3222"},{"key":"e_1_2_9_41_2","first-page":"1","article-title":"A randomised crossover comparison of controlled release hydromorphone tablets with controlled release morphine tablets in patients with cancer pain","volume":"2","author":"Moriarty M","year":"1999","journal-title":"J Clin Res."},{"key":"e_1_2_9_42_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.03.172"},{"key":"e_1_2_9_43_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0773.1990.tb00838.x"},{"key":"e_1_2_9_44_2","first-page":"653","article-title":"Control of severe pain with sustained\u2010release morphine tablets v. oral morphine solution","volume":"140","author":"Arkinstall WW","year":"1989","journal-title":"CMAJ."},{"key":"e_1_2_9_45_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1998.tb04380.x"},{"key":"e_1_2_9_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/0885-3924(92)90018-D"},{"key":"e_1_2_9_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0885-3924(97)00012-2"},{"key":"e_1_2_9_48_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.4.1004"},{"key":"e_1_2_9_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/0959-8049(94)90166-X"},{"key":"e_1_2_9_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/0885-3924(92)90017-C"},{"key":"e_1_2_9_51_2","first-page":"521","article-title":"Effects of controlled\u2010released morphine on quality of life for cancer pain","volume":"16","author":"Ferrell B","year":"1989","journal-title":"Oncol Nurs Forum."},{"key":"e_1_2_9_52_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.5.967"},{"key":"e_1_2_9_53_2","doi-asserted-by":"publisher","DOI":"10.2165\/00044011-199700141-00006"},{"key":"e_1_2_9_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3959(96)03269-1"},{"key":"e_1_2_9_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3959(89)90233-9"},{"key":"e_1_2_9_56_2","doi-asserted-by":"publisher","DOI":"10.2165\/00044011-199700141-00008"},{"key":"e_1_2_9_57_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2044.1987.tb04107.x"},{"key":"e_1_2_9_58_2","doi-asserted-by":"publisher","DOI":"10.1016\/0885-3924(94)00067-U"},{"key":"e_1_2_9_59_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2044.1989.tb09143.x"},{"key":"e_1_2_9_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3959(02)00328-7"},{"key":"e_1_2_9_61_2","first-page":"780","article-title":"[Morphine depot tablets compared with conventional morphine tablets in the treatment of cancer pain]","volume":"147","author":"Knudsen J","year":"1985","journal-title":"Ugeskr Laeger."},{"key":"e_1_2_9_62_2","first-page":"73","volume-title":"Advances in Morphine Therapy. The 1983 International Symposium on Pain Control.","author":"Kossmann B","year":"1984"},{"key":"e_1_2_9_63_2","first-page":"435","article-title":"The Brompton mixture versus morphine solution given orally: effects on pain","volume":"120","author":"Melzack R","year":"1979","journal-title":"Can Med Assoc J."},{"key":"e_1_2_9_64_2","doi-asserted-by":"publisher","DOI":"10.1016\/0885-3924(95)00063-5"},{"key":"e_1_2_9_65_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1090-3801(98)90020-9"},{"key":"e_1_2_9_66_2","doi-asserted-by":"publisher","DOI":"10.1177\/026921639701100608"},{"key":"e_1_2_9_67_2","first-page":"672","article-title":"Comparison of morphine slow release tablet (MST) and morphine sulphate solution (MSS) in the treatment of cancer pain","volume":"76","author":"Panich A","year":"1993","journal-title":"J Med Assoc Thai."},{"key":"e_1_2_9_68_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19890601)63:11<2284::AID-CNCR2820631137>3.0.CO;2-3"},{"key":"e_1_2_9_69_2","doi-asserted-by":"publisher","DOI":"10.1016\/0959-8049(94)90524-X"},{"key":"e_1_2_9_70_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3959(98)00019-0"},{"issue":"2","key":"e_1_2_9_71_2","first-page":"S55","article-title":"Morphine at gramme doses: kinetics, dynamics and clinical need","volume":"67","author":"Smith KJ","year":"1991","journal-title":"Postgrad Med J."},{"key":"e_1_2_9_72_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19890601)63:11<2275::AID-CNCR2820631136>3.0.CO;2-4"},{"key":"e_1_2_9_73_2","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3959(77)90072-0"},{"key":"e_1_2_9_74_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-6576.1988.tb02711.x"},{"key":"e_1_2_9_75_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0885-3924(86)80042-2"},{"key":"e_1_2_9_76_2","doi-asserted-by":"publisher","DOI":"10.1016\/0885-3924(89)90005-5"},{"key":"e_1_2_9_77_2","first-page":"137","article-title":"Sustained release morphine in cancer pain","volume":"9","author":"Vielvoye\u2010Kerkmeer A","year":"2002","journal-title":"Eur J Palliat Care."},{"key":"e_1_2_9_78_2","first-page":"727","article-title":"Clinical evaluation of slow release morphine tablets","author":"Walsh T.","year":"1985","journal-title":"Advances in Pain Research and Therapy."},{"key":"e_1_2_9_79_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-199206000-00018"},{"key":"e_1_2_9_80_2","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/oxfordjournals.annonc.a058765","article-title":"Oral tramadol, a mu\u2010opioid agonist and monoamine reuptake\u2010blocker, and morphine for strong cancer\u2010related pain","volume":"5","author":"Wilder\u2010Smith CH","year":"1994","journal-title":"Ann Oncol."},{"key":"e_1_2_9_81_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00685556"},{"key":"e_1_2_9_82_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3959(97)00072-9"},{"key":"e_1_2_9_83_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2004.03.003"},{"key":"e_1_2_9_84_2","doi-asserted-by":"publisher","DOI":"10.2165\/00044011-199714030-00004"},{"key":"e_1_2_9_85_2","first-page":"257","article-title":"Analgesic efficacy and side effects of oral tramadol andmorphine administered orally in the treatment of cancer pain","volume":"51","author":"Leppart W.","year":"2001","journal-title":"Nowotwory."},{"key":"e_1_2_9_86_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0885-3924(98)80004-3"},{"key":"e_1_2_9_87_2","first-page":"25","article-title":"Comparison of oral controlled\u2010release morphine with transdermal fentanyl in terminal cancer pain","volume":"35","author":"Wong JO","year":"1997","journal-title":"Acta Anaesthesiol Sin."},{"key":"e_1_2_9_88_2","first-page":"87","article-title":"Buprenorphine and sustained release morphine\u2014effects and side effects in chronic use","volume":"4","author":"Bach V","year":"1991","journal-title":"Pain Clinic."},{"key":"e_1_2_9_89_2","doi-asserted-by":"publisher","DOI":"10.1089\/1096621041349590"},{"key":"e_1_2_9_90_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19980315)82:6<1167::AID-CNCR23>3.0.CO;2-3"},{"key":"e_1_2_9_91_2","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3959(96)03112-0"},{"key":"e_1_2_9_92_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.10.3230"},{"key":"e_1_2_9_93_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0885-3924(98)00064-5"},{"key":"e_1_2_9_94_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601365"},{"key":"e_1_2_9_95_2","doi-asserted-by":"publisher","DOI":"10.1177\/00912700122010375"},{"key":"e_1_2_9_96_2","doi-asserted-by":"publisher","DOI":"10.1185\/030079904125003854"},{"key":"e_1_2_9_97_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19940915)74:6<1808::AID-CNCR2820740625>3.0.CO;2-Y"},{"key":"e_1_2_9_98_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(91)93401-T"},{"key":"e_1_2_9_99_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0885-3924(99)00036-6"},{"key":"e_1_2_9_100_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19970401)79:7<1428::AID-CNCR21>3.0.CO;2-0"},{"key":"e_1_2_9_101_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.5.1713"},{"key":"e_1_2_9_102_2","first-page":"129","volume-title":"Advances in Pain Research and Therapy Opioid Analgesics in the Management of Clinical Pain.","author":"Houde RW.","year":"1986"},{"key":"e_1_2_9_103_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0885-3924(02)00390-1"},{"key":"e_1_2_9_104_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3959(97)00018-3"},{"key":"e_1_2_9_105_2","doi-asserted-by":"publisher","DOI":"10.1191\/026921601669626431"},{"key":"e_1_2_9_106_2","doi-asserted-by":"publisher","DOI":"10.1089\/jpm.2000.3.49"},{"key":"e_1_2_9_107_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1090-3801(98)90046-5"},{"key":"e_1_2_9_108_2","doi-asserted-by":"publisher","DOI":"10.1016\/0885-3924(96)00191-1"},{"key":"e_1_2_9_109_2","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3959(89)90148-6"},{"key":"e_1_2_9_110_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0885-3924(99)00152-9"},{"key":"e_1_2_9_111_2","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3959(92)90034-9"},{"issue":"2","key":"e_1_2_9_112_2","first-page":"378","article-title":"Results of the clinical trial of transdermal therapeutic system\u2010fentanyl in strong opioid pre\u2010treated adult patients with cancer\u2010related pain","volume":"27","author":"Besova N","year":"2000","journal-title":"Gan Kagaku Ryoho."},{"key":"e_1_2_9_113_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3959(96)03254-X"},{"key":"e_1_2_9_114_2","doi-asserted-by":"publisher","DOI":"10.1016\/0885-3924(92)90056-N"},{"key":"e_1_2_9_115_2","doi-asserted-by":"publisher","DOI":"10.1016\/0885-3924(95)00162-X"},{"key":"e_1_2_9_116_2","first-page":"341","article-title":"Management of cancer\u2010related pain with transdermal fentanyl","volume":"79","author":"Leelanuntakt S.","year":"1996","journal-title":"J Med Assoc Thai."},{"key":"e_1_2_9_117_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0885-3924(98)00044-X"},{"key":"e_1_2_9_118_2","doi-asserted-by":"publisher","DOI":"10.1177\/026921639701100308"},{"key":"e_1_2_9_119_2","first-page":"93","article-title":"Transdermal fentanyl in cancer pain","volume":"6","author":"Ahmedzai S","year":"1994","journal-title":"J Drug Dev."},{"key":"e_1_2_9_120_2","doi-asserted-by":"publisher","DOI":"10.1016\/0885-3924(92)90057-O"},{"key":"e_1_2_9_121_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001813-199504003-00006"},{"key":"e_1_2_9_122_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0885-3924(97)00361-8"},{"key":"e_1_2_9_123_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0885-3924(01)00257-3"},{"key":"e_1_2_9_124_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.4.1588"},{"key":"e_1_2_9_125_2","doi-asserted-by":"publisher","DOI":"10.1163\/156856903321579334"},{"key":"e_1_2_9_126_2","unstructured":"PoulainP DenierW SeremetM KoberA SopataM.Analgesic efficacy and safety of transdermal buprenophine 70\u2003\u03bcg\/h in patients with severe chronic cancer pain. A randomised multicentre placebo\u2010controlled double\u2010blind study. Proceedings of the 4th Research Forum of the European Association for Palliative Care. Venice.2006."},{"key":"e_1_2_9_127_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(03)90019-1"},{"key":"e_1_2_9_128_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2004.11.008"},{"key":"e_1_2_9_129_2","first-page":"115","article-title":"Transdermal buprenorphine in the management of persistent pain\u2014safety asepcts","volume":"2","author":"Likar R.","year":"2006","journal-title":"Therapeutics Clin Risk Manage."},{"key":"e_1_2_9_130_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2005.04.007"},{"key":"e_1_2_9_131_2","doi-asserted-by":"publisher","DOI":"10.1185\/030079905X53315"},{"key":"e_1_2_9_132_2","doi-asserted-by":"publisher","DOI":"10.1213\/01.ANE.0000114085.20751.20"},{"key":"e_1_2_9_133_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(84)80023-6"},{"key":"e_1_2_9_134_2","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3959(86)90234-4"},{"key":"e_1_2_9_135_2","doi-asserted-by":"publisher","DOI":"10.1136\/pgmj.40.460.103"},{"key":"e_1_2_9_136_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.11.3656"},{"key":"e_1_2_9_137_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1977.tb00433.x"},{"key":"e_1_2_9_138_2","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3959(94)00257-F"},{"key":"e_1_2_9_139_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.11.2898"},{"key":"e_1_2_9_140_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0885-3924(99)00048-2"},{"key":"e_1_2_9_141_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a010679"},{"key":"e_1_2_9_142_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2354.1999.00133.x"},{"key":"e_1_2_9_143_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0885-3924(97)00082-1"},{"key":"e_1_2_9_144_2","first-page":"1931","article-title":"[Transdermal fentanyl for the management of cancer pain: a survey of 1,664 elderly patients]","volume":"83","author":"Yu SY","year":"2003","journal-title":"Zhonghua Yi Xue Za Zhi."},{"key":"e_1_2_9_145_2","first-page":"510","article-title":"A randomized vehicle\u2010controlled trial of topical capsaicin in the treatment of postherpetic neuralgia","volume":"15","author":"Watson CP","year":"1993","journal-title":"Clin Ther."},{"key":"e_1_2_9_146_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-199608020-00004"},{"key":"e_1_2_9_147_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199607043350107"},{"key":"e_1_2_9_148_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1990.33"},{"key":"e_1_2_9_149_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.45.12_Suppl_8.S58"},{"key":"e_1_2_9_150_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0885-3924(96)00180-7"},{"issue":"4","key":"e_1_2_9_151_2","first-page":"104","article-title":"Studies on the concomitant use of carbamazepine and clomipramine for the relief of post\u2010herpetic neuralgia","volume":"53","author":"Gerson GR","year":"1977","journal-title":"Postgrad Med J."},{"issue":"2","key":"e_1_2_9_152_2","first-page":"34","article-title":"[Treatment of post\u2010herpes zoster pain with tramadol. Results of an open pilot study versus clomipramine with or without levomepromazine]","volume":"53","author":"Gobel H","year":"1997","journal-title":"Drugs."},{"key":"e_1_2_9_153_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3959(02)00020-9"},{"key":"e_1_2_9_154_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002508-199909000-00004"},{"key":"e_1_2_9_155_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.160.6.853"},{"key":"e_1_2_9_156_2","unstructured":"KatzN ScheinJ KosinskiM.Sleep and somnolence changes in chronic low back pain patients receiving opioid therapy. Poster. In:Am Pain Soc.Chicago; 2003."},{"key":"e_1_2_9_157_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-002-0217-8"},{"key":"e_1_2_9_158_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0885-3924(98)00070-0"},{"key":"e_1_2_9_159_2","doi-asserted-by":"publisher","DOI":"10.4140\/TCP.n.2004.118"},{"key":"e_1_2_9_160_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0885-3924(03)00310-5"},{"key":"e_1_2_9_161_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.322.7295.1154"},{"key":"e_1_2_9_162_2","unstructured":"KatzN ScheinJ KosinskiM.HRQoL changes in chronic low back pain patients receiving either fentanyl transdermal system or oxycodone with acetaminophen. Poster. In:Am Pain Soc.Chicago; 2003."},{"key":"e_1_2_9_163_2","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/87.1.133"},{"key":"e_1_2_9_164_2","first-page":"1","article-title":"Fall injury episodes among noninstitutionalized older adults: United States, 2001\u20132003","volume":"21","author":"Schiller JS","year":"2007","journal-title":"Adv Data"},{"key":"e_1_2_9_165_2","first-page":"24","article-title":"Ambulante Schmerztherapie mit Opiaten","volume":"18","author":"Zenz M.","year":"1985","journal-title":"Diagnositk."},{"key":"e_1_2_9_166_2","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.1983.11698315"},{"key":"e_1_2_9_167_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra025411"},{"key":"e_1_2_9_168_2","doi-asserted-by":"publisher","DOI":"10.1016\/0885-3924(92)90059-Q"},{"key":"e_1_2_9_169_2","volume-title":"British National Formulary.","author":"British Medical Association and Royal Pharmaceutical Society of Great Britain.","year":"2005"},{"key":"e_1_2_9_170_2","volume-title":"Palliative Care Formulary.","author":"Twycross RG","year":"2007"},{"key":"e_1_2_9_171_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006146"},{"key":"e_1_2_9_172_2","first-page":"999","article-title":"Are opioids effective in the treatment of neuropathic pain?","volume":"75","author":"Guirguis\u2010Blake J","year":"2007","journal-title":"Am Fam Physician."},{"key":"e_1_2_9_173_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa021420"},{"key":"e_1_2_9_174_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2006.11.013"},{"key":"e_1_2_9_175_2","first-page":"95","article-title":"Clinical experience of pain treatment for postherpetic neuralgia in elderly patients","volume":"45","author":"Chau SW","year":"2007","journal-title":"Acta Anaesthesiol Taiwan."},{"key":"e_1_2_9_176_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2007.08.033"},{"key":"e_1_2_9_177_2","doi-asserted-by":"publisher","DOI":"10.1053\/eujp.2001.0307"},{"key":"e_1_2_9_178_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.58.4.554"},{"key":"e_1_2_9_179_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa042580"},{"key":"e_1_2_9_180_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.50.6.1837"},{"key":"e_1_2_9_181_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002508-200006001-00009"},{"key":"e_1_2_9_182_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000057720.36503.2C"},{"key":"e_1_2_9_183_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)09024-1"},{"key":"e_1_2_9_184_2","doi-asserted-by":"publisher","DOI":"10.1053\/eujp.2001.0240"},{"key":"e_1_2_9_185_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000539-199505000-00030"},{"key":"e_1_2_9_186_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0003-4975(97)82829-9"},{"key":"e_1_2_9_187_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3959(97)00172-3"},{"key":"e_1_2_9_188_2","doi-asserted-by":"publisher","DOI":"10.1213\/01.ANE.0000145066.06538.20"},{"key":"e_1_2_9_189_2","doi-asserted-by":"publisher","DOI":"10.1191\/0269216303pm815oa"},{"key":"e_1_2_9_190_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0885-3924(99)00049-4"},{"key":"e_1_2_9_191_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3959(03)00160-X"},{"key":"e_1_2_9_192_2","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1111\/j.1532-5415.1998.tb01084.x","article-title":"The management of chronic pain in older persons","volume":"46","author":"American Geriatrics Society, AGS Panel on Chronic Pain in Older Persons.","year":"1998","journal-title":"J Am Geriatr Soc."},{"key":"e_1_2_9_193_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.2006.01667.x"},{"key":"e_1_2_9_194_2","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3959(89)90097-3"},{"key":"e_1_2_9_195_2","first-page":"349","volume-title":"Opioid Sensitivity of Chronic Non\u2010Cancer Pain","author":"Evans PJD","year":"1999"},{"key":"e_1_2_9_196_2","first-page":"247","volume-title":"Pharmacological Approaches to the Treatment of Chronic Pain","author":"Portnoy RK","year":"1994"},{"key":"e_1_2_9_197_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002508-199206000-00003"},{"key":"e_1_2_9_198_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.1977.hed1701012.x"},{"key":"e_1_2_9_199_2","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3959(82)90016-1"},{"key":"e_1_2_9_200_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198001103020221"},{"key":"e_1_2_9_201_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-6576.1997.tb04634.x"},{"key":"e_1_2_9_202_2","doi-asserted-by":"publisher","DOI":"10.5414\/CPP38504"},{"key":"e_1_2_9_203_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0024-3205(97)00160-4"},{"key":"e_1_2_9_204_2","first-page":"257","article-title":"Inhibition of methadone and buprenorphine N\u2010dealkylations by three HIV\u20101 protease inhibitors","volume":"26","author":"Iribarne C","year":"1998","journal-title":"Drug Metab Dispos."},{"key":"e_1_2_9_205_2","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.25.682"},{"key":"e_1_2_9_206_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.31.6.768"},{"key":"e_1_2_9_207_2","unstructured":"National Disease and Therapeutic Index (NDTI).http:\/\/www.ndti.org."},{"key":"e_1_2_9_208_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.2005.25.11.1636"},{"key":"e_1_2_9_209_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.289.9.1107"},{"key":"e_1_2_9_210_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-197917020-00001"},{"key":"e_1_2_9_211_2","first-page":"818","article-title":"Human buprenorphine N\u2010dealkylation is catalyzed by cytochrome P450 3A4","volume":"26","author":"Kobayashi K","year":"1998","journal-title":"Drug Metab Dispos."},{"key":"e_1_2_9_212_2","first-page":"1","article-title":"Human UGT2B7 catalyzes morphine glucuronidation","volume":"25","author":"Coffman BL","year":"1997","journal-title":"Drug Metab Dispos."},{"key":"e_1_2_9_213_2","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/61.5.569"},{"key":"e_1_2_9_214_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000539-199601000-00031"},{"key":"e_1_2_9_215_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-6576.2008.01597.x"},{"key":"e_1_2_9_216_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2006.01.009"},{"key":"e_1_2_9_217_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270004271969"},{"key":"e_1_2_9_218_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0773.1998.tb01573.x"},{"key":"e_1_2_9_219_2","doi-asserted-by":"publisher","DOI":"10.1191\/096032798678908837"},{"key":"e_1_2_9_220_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000542-199909000-00020"},{"key":"e_1_2_9_221_2","unstructured":"Ortho\u2010McNeil Pharmaceutical I.Ultram\u00ae (tramadol hydrochloride tablets). Full Prescribing Information. Raritan NJ; February 2007."},{"key":"e_1_2_9_222_2","unstructured":"Endo Pharmaceuticals.OPANA\u00ae ER Tablets. Full Prescribing Information. Chadds Ford PA;September 2007."},{"key":"e_1_2_9_223_2","unstructured":"Purdue Pharma LP.OxyContin\u00ae (oxycodone HCL controlled\u2010release) Tablets. Full Prescribing Information. Stamford CT; November 2007."},{"key":"e_1_2_9_224_2","unstructured":"Abbott Laboratories.Vicodin\u00ae (hydrocodone bitartrate and acetaminophen tablets USP) 5 mg\/500 mg. Full Prescribing Information. North Chicago IL; March 2007."},{"key":"e_1_2_9_225_2","unstructured":"UCB Pharma I.Lortab\u00ae 10\/500 (hydrocodone bitartrate and acetaminophen tablets USP 10 mg\/500 mg). Full Prescribing Information. Smyrna GA; March 2004."},{"key":"e_1_2_9_226_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2003.02002.x"},{"key":"e_1_2_9_227_2","unstructured":"Endo Pharmaceuticals.Percocet\u00ae (oxycodone and acetaminophen tablets USP). Full Prescribing Information. Chadds Ford PA; November 2006."},{"key":"e_1_2_9_228_2","unstructured":"Roxane Laboratories I.Codeine Sulfate Tablets USP. Full Prescribing Information. Columbus OH; August 2007."},{"key":"e_1_2_9_229_2","doi-asserted-by":"publisher","DOI":"10.1177\/0310057X0002800602"},{"key":"e_1_2_9_230_2","unstructured":"King Pharmaceuticals.Avinza\u00ae (morphine sulfate extended\u2010release capsules). Full Prescribing Information. Bristol TN; October 2006."},{"key":"e_1_2_9_231_2","unstructured":"Alpharma PharmaceuticalsLLC.Kadian\u00ae (morphine sulfate extended\u2010release) Capsules. Full Prescribing Information. Piscataway NJ; April 2007."},{"key":"e_1_2_9_232_2","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/aei145"},{"key":"e_1_2_9_233_2","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1191\/0269216303pm838cr","article-title":"Severe respiratory depression and sedation with transdermal fentanyl: four case studies","volume":"17","author":"Regnard C","year":"2003","journal-title":"Palliat Med."},{"key":"e_1_2_9_234_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1994.71"},{"key":"e_1_2_9_235_2","volume-title":"New Insights Into Buprenorphine's Respiratory Effects.","author":"Dahan A.","year":"2005"},{"key":"e_1_2_9_236_2","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/aeg150"},{"key":"e_1_2_9_237_2","volume-title":"Respiratory Pharmacology","author":"Ward D","year":"2004"},{"key":"e_1_2_9_238_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-2143(97)90193-1"},{"key":"e_1_2_9_239_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.exger.2004.06.009"},{"key":"e_1_2_9_240_2","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.1103592"},{"key":"e_1_2_9_241_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-5728(97)00217-8"},{"key":"e_1_2_9_242_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(93)90508-T"},{"key":"e_1_2_9_243_2","doi-asserted-by":"publisher","DOI":"10.1159\/000078444"},{"key":"e_1_2_9_244_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2004.04.020"},{"key":"e_1_2_9_245_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000539-199603000-00011"},{"key":"e_1_2_9_246_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0192-0561(99)00025-9"},{"key":"e_1_2_9_247_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0701138"},{"key":"e_1_2_9_248_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2007.01.001"},{"key":"e_1_2_9_249_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1521-6616(03)00177-3"},{"key":"e_1_2_9_250_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000539-200006000-00028"},{"key":"e_1_2_9_251_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000542-199509000-00008"},{"key":"e_1_2_9_252_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF03020942"}],"container-title":["Pain Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1533-2500.2008.00204.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1533-2500.2008.00204.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T07:39:32Z","timestamp":1697096372000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1533-2500.2008.00204.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7]]},"references-count":251,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,7]]}},"alternative-id":["10.1111\/j.1533-2500.2008.00204.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1533-2500.2008.00204.x","archive":["Portico"],"relation":{},"ISSN":["1530-7085","1533-2500"],"issn-type":[{"value":"1530-7085","type":"print"},{"value":"1533-2500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,7]]}}}